Treatment of Tuberculous Meningitis in Adults with HIV Co-infection
This protocol addresses anti-tuberculosis treatment for hospitalised adults aged 18 years or older diagnosed with tuberculous meningitis who also have HIV co-infection — a combination that requires particular consideration of both tuberculosis therapy sequencing and antiretroviral therapy timing.
Clinical Scenario
Age ≥ 18 years
Tuberculous meningitis
HIV co-infection
Adults requiring hospital treatment for tuberculous meningitis in the setting of HIV co-infection. The presence of HIV meaningfully shapes both the choice of adjunctive interventions and the timing of antiretroviral therapy initiation relative to tuberculosis treatment.
Treatment Approach (Partial Overview)
Management centres on a structured course of anti-tuberculosis therapy, with drug selection informed by local resistance patterns. Adjunctive corticosteroids may be considered on a case-by-case basis, weighing individual benefits and risks in people living with HIV. Antiretroviral therapy timing relative to the start of tuberculosis treatment is a key decision point, with the approach varying based on CD4 count and clinical status. The complete regimen — including phasing, duration, and all decision rules — is in the full protocol.
References
- Population: adults in hospital requiring treatment for tuberculous meningitis with HIV co-infection.
- Is there HIV co-infection? — high certainty of evidence, weak recommendation for use of adjunctive corticosteroids in people living with HIV; decision should be made on a case-by-case basis.
- Adults: RHZE with quinolone if at high risk of isoniazid resistance.
- In the absence of an effective alternative adjunctive therapy for HIV-associated tuberculous meningitis, and given the safety and potential effectiveness of corticosteroids, their use is recommended on a case-by-case basis in people living with HIV.
- If not already on ART, initiate at week 4–8 unless there is a clinical need for earlier initiation; if CD4 count less than 50 cells per mm³, consider ART at 2 weeks where there is an urgent clinical need.
- These limited data inform the weak recommendation to defer antiretroviral therapy for 4–8 weeks after starting tuberculosis treatment, in agreement with WHO and other guidelines.
DOI: 10.1016/S1473-3099(25)00364-0
View source ↗